Company intelligence / Profile preview

Leucadia Therapeutics

Riverside, California, United Statesleucadiatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Leucadia Therapeutics has developed a novel implantable medical device called Arethusta®, designed to restore CSF flow and flush neurotoxic substances from the brain. The company claims this approach may prevent or even reverse Alzheimer’s pathology. They are enrolling participants in a large-scale clinical study ("Project Cribrose") to refine their diagnostic tools and assess risk for Alzheimer’s. No published late-stage clinical results yet.

Therapeutic areas: Neurology
Modalities: Medical device (Arethusta®)small molecule drugs (possible, but primary focus on device)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Arethusta

Pre-clinical

Indications: Alzheimer's disease, Mild cognitive impairment

Partnerships

Arrowhead Regional Medical Center (clinical collaboration on Project Cribrose)

Beyond the preview

Go deeper on Leucadia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leucadia Therapeutics.

Explore the full profile